Skip to content
Shuttingdown

Apellis Pharmaceuticals, Inc.

Pharmaceutical Preparations · WALTHAM · MA

No longer listed

High confidence (85%)

Updated Oct 7, 2026, 12:04 AM

What is happening

Derived by rule set status-rules-2026.09.7

The company deregistered its securities and stopped filing with the SEC. Companies do that when they are acquired, when they go private, and when they fail; the filing does not say which.

Latest material event: Apellis Pharmaceuticals, Inc. deregistered its securities (May 26, 2026)

Timeline

Every material event, newest first. History is never overwritten.

  1. Apellis Pharmaceuticals, Inc. deregistered its securities

    May 26, 2026

    Registration withdrawn

    • SEC EDGAR — “15-12G 1 form15-12g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38276 Apellis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) 100 Fifth Avenue Waltham, MA 02451 (617) 977-5700 (Address, including zip code, and telephone number, including area code, of registrant’s principal ex…”

  2. Apellis Pharmaceuticals, Inc. received a delisting notice from its exchange

    May 14, 2026

    Delisting notice received

    • SEC EDGAR — “Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 13, 2026, the Company (i) notified The Nasdaq Stock Market ( Nasdaq ) of the anticipated consummation of the Merger and (ii) requested that Nasdaq (x) suspend trading of the Shares, effective at 8:00 p.m., Eastern Time, on May 13, 2026, and, following the Effective Time, (y) file with the U.S. Securities and Exchange Commission (the SEC ) a Form 25, Notification of Removal from Listing and/or Registration, to delist and deregister the Shares under Section 12(b) of the Securitie…”

  3. Apellis Pharmaceuticals, Inc. was delisted from its exchange

    May 14, 2026

    Delisting effective

    • SEC EDGAR — “X0203 0001354457 Nasdaq Stock Market LLC 0001492422 Apellis Pharmaceuticals, Inc. 001-38276 6400 Westwind Way Suite A Crestwood KY KENTUCKY 40014 502-241-4114 Common Stock 17 CFR 240.12d2-2(a)(3) Katelin Rowe CDO Analyst 2026-05-14”

Company information

Founded
—
Employees (estimate)
—
Industry
Pharmaceutical Preparations
Subindustry
—
SEC CIK
0001492422
Website
—
LinkedIn
—
Headquarters
WALTHAM, MA
Also known as
—
Legal entities
Apellis Pharmaceuticals, Inc.

Sources

Every material source used to build this profile.

  • SEC Company Submissions (TIER 1 · UNVERIFIED)

    Apellis Pharmaceuticals, Inc. — Pharmaceutical Preparations (SIC 2834) — WALTHAM, MA
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    15-12G 1 form15-12g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38276 Apellis Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) 100 Fifth Avenue Waltham, MA 02451 (617) 977-5700 (Address, including zip code, and telephone number, including area code, of registrant’s principal ex…
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    X0203 0001354457 Nasdaq Stock Market LLC 0001492422 Apellis Pharmaceuticals, Inc. 001-38276 6400 Westwind Way Suite A Crestwood KY KENTUCKY 40014 502-241-4114 Common Stock 17 CFR 240.12d2-2(a)(3) Katelin Rowe CDO Analyst 2026-05-14
    View source record

  • SEC EDGAR (TIER 1 · UNVERIFIED)

    Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 13, 2026, the Company (i) notified The Nasdaq Stock Market ( Nasdaq ) of the anticipated consummation of the Merger and (ii) requested that Nasdaq (x) suspend trading of the Shares, effective at 8:00 p.m., Eastern Time, on May 13, 2026, and, following the Effective Time, (y) file with the U.S. Securities and Exchange Commission (the SEC ) a Form 25, Notification of Removal from Listing and/or Registration, to delist and deregister the Shares under Section 12(b) of the Securitie…
    View source record

Status history

Every derived status, with the rule that produced it.

  • DISTRESS_SIGNAL → NO_LONGER_LISTEDPUBLIC_LISTING_ENDED · Sep 18, 2026, 01:29 AM

    The company deregistered its securities and stopped filing with the SEC. Companies do that when they are acquired, when they go private, and when they fail; the filing does not say which.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALLISTING_STANDARDS_WARNING · Sep 18, 2026, 01:13 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 15, 2026, 12:32 PM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 14, 2026, 04:45 PM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • DISTRESS_SIGNAL → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 04:40 AM

    The company stopped being publicly listed. That happens to failing companies and to acquired ones alike.

  • UNKNOWN → DISTRESS_SIGNALPUBLIC_LISTING_ENDED · Sep 8, 2026, 04:40 AM

    An exchange warned the company it no longer meets the listing standards. Companies regain compliance often.